Precision BioSciences
DTIL
48 hedge funds and large institutions have $18.1M invested in Precision BioSciences in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 12 closing their positions.
23% more capital invested
Capital invested by funds: $14.7M → $18.1M (+$3.35M)
13% less funds holding
Funds holding: 55 → 48 (-7)
14.45% less ownership
Funds ownership: 50.58% → 36.13% (-14%)
18% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 11
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$1.02M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$966K |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$965K |
| 4 |
Millennium Management
New York
|
+$334K |
| 5 |
TC
Tejara Capital
London,
United Kingdom
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.15M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$586K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$381K |
| 4 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
-$229K |
| 5 |
Squarepoint
New York
|
-$179K |
DTIL Hedge Fund Activity: Q1 2025 in Review
48 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Precision BioSciences (DTIL) for Q1 2025, worth a combined $18.1M — up 23% from $14.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DTIL and 6 opened new positions — a net loss of 6 holders — while 11 trimmed existing stakes and 9 added.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $1.02M. The largest seller was Goldman Sachs, exiting entirely with an estimated $1.15M sold.
- 48 institutional investors held Precision BioSciences (DTIL) as of Q1 2025, down from 55 in Q4 2024.
- Funds reported $18.1M of Precision BioSciences stock for Q1 2025, up 23% quarter-over-quarter.
- 6 funds opened new Precision BioSciences positions in Q1 2025 and 12 closed out, a net change of -6 holders.
- The largest Precision BioSciences buyer in Q1 2025 was Boothbay Fund Management, an estimated $1.02M added.
- The largest Precision BioSciences seller in Q1 2025 was Goldman Sachs, an estimated $1.15M sold.
Based on aggregated 13F filings for Q1 2025.